P. Gates
St. Vincent's Health System
9 Papers
61 Citations
P. Gates is an academic researcher from St. Vincent's Health System. The author has contributed to research in topics: Metastatic breast cancer & Chemotherapy. The author has an hindex of 6, co-authored 7 publications.
Chat about Author
Papers
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: Results of a phase I study
Henry Miles Prince,Michael Millward,Danny Rischin,D. Blakey,Prudence A. Francis,P. Gates,P. Chappie,Michael A. Quinn,Surender Juneja,Max Wolf,EH Januszewicz,John F. Seymour,M Brettell,Andrew Strickland,John Zalcberg,G Richardson,J. Scarlett,P. Briggs,G. C. Toner +18 more
TL;DR: The recommended doses for phase II or III studies are ifosfamide (10 g/m2), thiotepa (350 mg/ m2) and paclitaxel (175 mg/M2).
18
Docetaxel effectively mobilizes peripheral blood CD34+ cells.
Henry Miles Prince,G. C. Toner,John F. Seymour,D. Blakey,P. Gates,S Eerhard,P Chapple,D. Wall,Michael A. Quinn,Surender Juneja,Max Wolf,EH Januszewicz,G Richardson,J. Scarlett,P. Briggs,M Brettell,Danny Rischin +16 more
TL;DR: It is concluded that docetaxel with G-CSF effectively mobilises PBPCs with apheresis needing to be commenced approximately 8 days after docetrixel administration.
16
Comparison of COBE Spectra software version 4.7 PBSC and version 6.0 auto PBSC program.
Wilke R,M Brettell,Prince Hm,Wolf M,McKenna R,Serpell E,M Molloy,H Stevens,Michael A. Quinn,P. Gates,P Chapple +10 more
TL;DR: The COBE® Spectra™ Version 6.0 apheresis device offers the user an automated program for the collection of PBPC and the results showed no statistical difference between results obtained when the starting PB CD34+ cell count was 10–50×106/L or >50 × 106/L.
16
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Henry Miles Prince,Danny Rischin,G. C. Toner,John F. Seymour,D. Blakey,P. Gates,S Eerhard,P Chapple,Michael A. Quinn,M Brettell,Surender Juneja,Max Wolf,EH Januszewicz,G Richardson,J. Scarlett,P. Briggs +15 more
TL;DR: This phase I study found the optimal dosages of a novel repetitive high-dose therapy regimen for patients with metastatic breast cancer to be cyclophosphamide, thiotepa and docetaxel, supported by peripheral blood progenitor cells (PBPC) and filgrastim.
12
Symptomatic and asymptomatic carotid stenosis: Just when we thought we had all the answers
TL;DR: Signals for this procedure include participation in randomized controlled trials, surgically inaccessible stenosis, in patients with combined symptomatic carotid and symptomatic coronary artery disease or in Patients with severe co‐morbidities that preclude formal Carotid endarterectomy.
12